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license (http://creativecommons.org/Summary Osteoarthritis (OA) is the most common degenerative joint disorder. OA was
conceived as a “wear and tear” problem of articular cartilage, yet there is a lack of treatment
options to delay or rescue articular cartilage degeneration once it is established. Actually, the
degradation of articular cartilage is related to a complex network of biochemical pathways
involving the diffusion of catabolic factors within and between different joint tissues and
particularly bone and cartilage. Advanced proteomics technology provides a powerful tool
to allow us to build up a library of such factors. Factors that govern the bone-cartilage inter-
play could be the candidate diagnostic biomarkers and therapeutic targets for OA. Currently, a
growing body of proteomic studies has been done to unveil a number of inflammatory cyto-
kines, proteases, and cartilaginous matrix cleavages in the blood serum, synovial fluid, and
articular cartilage from OA patients. Little information is available regarding the protein pro-
files of disturbances at subchondral bone in the pathophysiology of OA. The technical diffi-
culties in protein extraction from tissues particularly bone and quantitative analyses of
protein profile are discussed; cellular proteomics of the defective osteoblasts and secretomics
for the osteoblastsechondrocytes crosstalk are proposed to supplement the information ob-
tained from the bone tissue proteomics.
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Osteoarthritis (OA) is a prevalent debilitating whole-joint
disorder, which commonly afflicts the load-bearing joints
such as knees and hips [1]. OA is a major cause for joint pain
and disability in elderly people. The hallmark of OA is loss
of articular cartilage, which cushions the joint during
movement. Yet the integrity of articular cartilage relies on
the interplay with other joint tissues, particularly sub-
chondral bone [2]. Given the lack of treatment options to
delay or rescue degradation of articular cartilage, bone
antiresorptives and anabolics are recently the candidate
treatments for OA [3]. Yet the factors or mediators that
govern the bone-cartilage interactions in the pathogenesis
of OA remain largely unknown.
Proteomics, a large-scale analysis of proteins that in-
volves isolation, purification, and mass spectrometry of
proteins of interest, makes it possible to search such fac-
tors or mediators in a systemic fashion. Proteomic tech-
nologies have been widely adopted in studying various
rheumatic diseases [4e10]. Development of high-
throughput and high sensitivity mass spectrometry has
opened a door to look into the proteins and peptides con-
tained in body fluids and joint tissues [11,12]. Synovial fluid
and serum are the frequently studied specimens whereas
synovial and cartilaginous tissues were studied in only a
handful of studies. To the best of our knowledge, OA sub-
chondral bones have yet to be studied due to some tech-
nique challenges in the protein extraction, purification, and
identification process. With the advancement of proteomic
technologies, it allows us to study the proteins or peptides
inside bone that are likely to participate in the interplay
between bone and cartilage in the pathogenesis of OA.
To the best of our knowledge, little information is
available regarding the challenges and perspectives of
subchondral bone and cell proteomics in the context of OA
pathophysiology, which is the motivation of this review
article.Tissue proteomics in OA
The past decade has witnessed the values of proteomic
technology in identification of biomarkers and therapeutic
targets for various arthritis and rheumatic disorders. Pro-
teomics, i.e., establishing a library of proteins and peptides
of interest, enables us to delineate the diseased status
from their healthy counterparts. Synovial fluid is the most
commonly studied specimen in the field of arthritis and
rheumatology research. As a dialysate of plasma, synovial
fluid contains a much lower concentration of high molecu-
lar weight proteins than plasma, and its total amount of
proteins is also 30% lower than plasma in physiological
conditions [13]. In an inflamed joint, proteins in the blood
stream can enter synovial fluid freely due to an increase in
blood vessel numbers and permeability. Over 100
inflammation-related proteins such as apolipoproteins,
complements, and fibrinogens have already been identified
in synovial fluid samples from OA patients [14e16]. Their
biochemical functions could be grouped into three domi-
nant pathways: acute phase response signalling, comple-
ment pathway, and coagulation pathway. Apolipoproteinsmight originate from systemic metabolism and comple-
ments could be produced locally by synoviocytes. A
degraded derivative of complement 3f (C3f) was identified
in synovial fluid (SF) of OA patients [15]. C3f, a plasma zinc
metalloproteinase, was known as an inflammatory regu-
lator and is related to vascular involvement in another
rheumatic disorder d systemic sclerosis [17]. Ligands for
toll-like receptors such as hyaluronic acid, fibronectin, and
alarmins (S100 proteins) were also detected in OA synovial
fluid [18]. They induce macrophages and synoviocytes to
produce inflammatory cytokines, mediating the catabolic
responses in degenerative process of articular cartilage.
Inflammation-related proteins are not only produced in the
late-stage, but also in the early stages of OA. This implies
that innate immunity might contribute to the onset and
progression of OA. Meanwhile, it was not surprising to note
a decrease in cysteine proteases inhibitors level in OA sy-
novial fluid [14], which failed to protect aggrecan from
degradation. As a consequence, the level of extracellular
matrix proteins, e.g., aggrecan and cartilage oligomatrix
protein, were significantly increased in OA synovial fluid
[9].
Although some meaningful results have been produced,
the technical challenges in proteomic studies on OA syno-
vial fluid have to be addressed. Firstly, the abundant pro-
teins in synovial fluid such as various extracellular matrix
components and albumins may mask the minutely present
proteins, e.g., inflammatory cytokines. Structural proteins
could be depleted via immunodepletion or two-dimensional
cleanup kits [10,15]. Acetone precipitation, despite being a
fairly commonly used technique for proteome study, should
not be employed because it lowers the overall protein
concentration, including the target proteins [19]. Multiple
fractionations involving SDSepolyacrylamide gel electro-
phoresis (PAGE) for protein level and SCX-Offgel at peptide
level could significantly reduce the complexity of the
sample [20] and hugely increased the number of newly
identified novel proteins. The greatest hurdle to be over-
come, however, is that it is very difficult to find a healthy
control for OA proteomics study. Usually, synovial fluid
samples from rheumatoid arthritis (RA) patients are being
compared, which may not expand our understanding in OA.
Synovial fluid is partly produced by synovium, a thin
lining in the joint cavity responsible for homeostasis and
joint functions. Fibroblast-like synoviocytes is the major
cell type in synovium, which can synthesize hyaluronic acid
to stabilize water content in synovial fluid and lubricate the
articular surfaces during joint movements. Synovial tissues
were often investigated in RA, and OA synovium usually
serves as a “noninflammatory” control. A transcriptome-
proteome combined study on RA and OA synovial tissue
demonstrated that many gene expression changes did not
coincide at transcription and protein levels, again verifying
the need of a more powerful proteome study [8]. To further
investigate the physical distribution of proteins, a study
involving Matrix-assisted laser desorption/ionization mass
spectrometry (MALDIeMS) imaging was performed and this
technique involves the use of digital photography of stained
histological sections of synovium and MALDI mass spec-
trometry. Interestingly, the expression of thymosin beta-4,
responsible for T-lymphocyte maturation, increased in sy-
novial lining of both RA and OA samples. This finding did
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pathologies of both RA and OA.
Proteomic analysis of articular cartilage will provide a
direct insight into the pathogenesis of OA; yet articular
cartilage is mainly composed of extracellular matrix
including collagens and proteoglycans and dominance of
such components limits identification of the less abundant
signalling proteins produced by articular chondrocytes.
Various robust and reliable extractioneseparation protocols
were proposed including the use of urea-free solvent and
high molecular weight filter, etc. [21e23]. However, only
proteins ofw 100 kDa were collected, suggesting a need for
optimizing the existing extractioneseparation protocols.
Despite exhaustive removal processes, abundant proteins
are still present as contaminants. For example, highly
anionic macromolecules such as aggrecan and hyaluronic
acid are exceptionally hard to completely remove for pro-
teomic analysis of articular cartilage. The technical limi-
tations aside, proteomic study of OA cartilage uncovered a
similar protein profile as in synovial fluid including the
complements, immunoglobulin chains, thrombopoietin,
fibrinogen, etc. [21]. Besides, a comparative study was
performed on lateral and medial articular chondrocytes
from OA patients [24]. Chondrocytes from the less damaged
lateral side produced more proteins responsible for actin
cytoskeleton organization, glucose metabolic process, and
antiapoptosis. On the severely damaged medial side,
chondrocytes tended to express more inflammatory cyto-
kines and acute response phase mediators. This indicates
that degradation of articular cartilage occurs in the in-
flammatory environment of synovial fluid.
Proteomic analyses of serum are the most challenging
among all the previously performed OA proteome studies.
The serum protein profile is affected by an assortment of
variables such as the donors’ health conditions, age, and
physique; thus making it very hard to study without inter-
ference from the said constraints. To make matters more
complicated, serum is rich in “abundant proteins”, just the
“top eight” highly abundant proteins make up 85% of the
protein content, and 14 other moderately abundant proteins
make up 14%, meaning the remaining make up only 1% by
mass. Therefore, immunodepletion of abundant protein via
affinity columns is commonly adopted. A separate depletion
step for albumin with a high capacity immunodepletion
column prior to the depletion of the other seven highly
abundant proteins was found to yield better results than just
performing in one single column; but because the depletion
step results in the dilution of proteins, a concentration step
is required after the immunodepletion. A chemical sequen-
tial depletion method using Dithiothreitol (DTT) to remove
proteins rich in disulphide bonds such as albumin followed by
acetonitrile depletion of high molecular weight proteins of
over 75 kDa is also viable [25]. De Seny et al [26] had utilized
gene chip arrays in his investigation, hence eliminating the
need for exhaustive sample treatments altogether. The
downside of Surface-enhanced laser desorption/ionization
(SELDI) though is that the protein chip can only detect a
limited number of proteins of certain biochemical properties
and functions instead of the entire protein profile, hence
requiring multiple chips to cover a wider spectrum.
Numerous potential serum biomarkers for OA have been
named in several proteome studies [27], which can becategorized into metabolic and immune regulators such as
apolipoproteins, adiponectins, haptoglobin truncated pro-
teins, interleukin 1b and 6; or metabolites of extracellular
matrix, e.g., C-terminal telopeptide of collagen type II
(CTX-II) and cartilage oligomatrix protein (COMP). Poor
reliability of CTX-II and COMP as OA biomarkers, in spite of
their close associations with the disease severity of OA,
stops them from being extensively used for OA screening
[28]. Glycosylation and other posttranslational modifica-
tions of proteins are also important in the discovery of
biomarkers. Fukuda et al [28] had performed the first gly-
coproteomic study on OA using the N-Glycoproteomic 2D-
LC-MALDI approach, in which glycoproteins in plasma were
specifically concentrated using Affi-Gel Hz hydrazide gel
and the trypsin-digested glycoproteins were subjected to
comprehensive analysis by 2D-LC-MALDI. It is worth
mentioning that glycoproteomic studies do not only eval-
uate the amount of proteins, but also the level of glyco-
sylation of that protein. For example, ELISA did not detect
any significant difference on acute-phase inflammatory
response proteins such as clusterin and hemopexin between
progressive and nonprogressive OA samples; but the
significantly increased glycosylation level of these proteins
in progressive OA samples implicated the glycosylation of
proteins as the biomarkers for disease progression.Bone and osteoblasts proteomics in OA
It has been well received that the homeostasis of articular
cartilage relies on the biochemical and biomechanical
interplay with subchondral bone [2]. It was proposed several
decades ago that hardening of subchondral bone would in-
crease the “wear and tear” risk of articular cartilage [29].
The expansion of subchondral bone size correlated with
cartilage loss in OA patients [30]. The relationship between
bone and cartilage in pathogenesis of OAmay be described as
“shoe” and “foot”. The disproportional changes of sub-
chondral bone (“shoe”) and overlying cartilage (“foot”) will
lead to a “wear and tear” problem. Yet the factors or me-
diators that govern the hypertrophic changes of subchondral
bone in OA remain largely unknown.
Bone protein profiles provided a unique tool to differ-
entiate osteopenia from OA as compared with serum pro-
teins [31]. As identified in proteomic analyses of bone from
femoral neck, metabolic enzymes, such as carbonic anhy-
drase I and phosphoglycerate kinase 1, were the most sig-
nificant variations of proteins in patients with various bone
disorders. In addition, the amount of transforming growth
factor-b1 (TGFb1), insulin-like growth factor (IGF-1), and
osteocalcin that embedded in bone matrices from the iliac
crest were much higher in patients with generalized OA
than healthy patients [32]. Among these factors, a high
level of TGF-b1 had been proven to account for OA osteo-
blasts dysfunctions and subchondral bone disturbances
[33,34]. Serum level of active TGFb1 was identified as a
prognostic biomarker for the progression of OA in animal
models [35], although it remained controversial [36].
Collectively, all these data indicated the need for bone
proteomics in OA research.
It is technically challenging to extract the proteins of
interest from bone that contains the greatest abundance
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was employed to demineralize bone tissue in an attempt
to improve the efficiency of protein extraction [37]. We
have adopted a similar strategy, using the HCl deminer-
alization procedure as the first step followed by urea-
based protein extraction from OA subchondral bone in a
trial. Samples were sent for MS analysis by LC-MS/MS LTQ-
Orbitrap (LTQ-Orbitrap Velos, Thermo Scientific, MA, USA)
and data were analyzed with Maxquant against human
database using default settings (version 1.3.0.5). A major
lesson learned from the trial is that deep frozen samples
kept at 80C for > 1 week failed to yield any significant
signal, suggesting that fresh samples are a must for
effective protein extraction. As shown in Fig. 1, a total of
163 and 119 proteins have been successfully identified in
fresh articular cartilage and subchondral bone respec-
tively. This protein extraction strategy seems to work for
both cartilage and bone tissues. It is very interesting to
distinguish patterns of protein profiles in lateral and
medial compartments (less or severely damaged parts) of
osteoarthritic joints. Less and severely damaged cartilage
shared nearly one-third of the proteins identified,
whereas 62 and 50 distinct proteins were found only in
either the lateral or medial compartments respectively.
The striking different protein expression pattern was inFigure 1 A trial for subchondral bone proteomics in osteoarthrit
during its progression process (A). In our recent trial for subchon
differential protein profiles of articular cartilage (B, C) and subchon
of diseased joints, which is subject to varied mechanical loading athe subchondral bone, where the lateral and medial sides
only shared 7 proteins.
The differential protein expression pattern suggests a
distinguished signalling mechanism in the corresponding
bone region echo to the different stage or severity of OA.
However, the data warrants a further validation study.
While the pilot data seems promising, we still need to point
out that most of the proteins identified are still extracel-
lular matrix (ECM) proteins and we cannot exclude the
possibility that the variation in different regions is simply
due to experimental error. As a result, further experiments
need to confirm the unique protein expression patterns and
we should also address the issues regarding the high-
abundance of ECM proteins in future experiments. The
urea-based extraction buffer made the depletion of high-
abundance proteins impossible. SDSePAGE molecular
weight-based fractionation step is, however, possible. This
added dimension of separation is expected to increase the
number of proteins identified and reduce the effect of
highly abundant proteins. Meanwhile we also noticed a
recent report showing that phenol extraction could effec-
tively reduce the amount of hyaluronan and proteoglycans
[38]. We are going to adopt this method to further improve
our current protocol in order to generate much more
meaningful information regarding protein expressionis. Proteomics will provide a snapshot for the status of disease
dral bone proteomics in osteoarthritis samples, we identified
dral bone (D, E) between the lateral and medial compartments
nd also exhibited different severities of joint damage.
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samples.
Osteoblast dysfunction has been documented in the
pathogenesis of disturbances at subchondral bone and OA.
It was demonstrated that osteoblasts derived from sclerotic
bone region overproduced collagen type I with the wrong
composition and poor mineralization [39], and also
expressed a high level of inflammatory cytokines such as
TGFb1, prostaglandin E2, interleukin 1b and 6, etc. [33].
They could induce a procatabolic phenotype in healthy
chondrocytes, by increasing the expression of MMP-3 and 13
and reducing the production of aggrecan [40,41]. However,
there is little information regarding a complete protein
expression profile of defective osteoblasts in OA whereas
two proteomic studies into the OA bone marrow derived
mesenchymal progenitors, which give rise to osteoblasts
[42,43]. As reported, a high percentage of metabolic en-
zymes were increased and most of the proteins related to
cytoskeleton/motility were decreased in mesenchymal
progenitors of OA. However, it could not explain the
enhanced migration response of mesenchymal progenitors
to platelet-derived growth factor-BB with decreased cyto-
skeleton/motility proteins in the same study [42]. In the
other proteomic study, the increased cytoskeletal proteins,
such as beta actin and alpha tubulin were identified in OA
compared with RA [43].
Besides bone cell proteomics, a boneecartilage
communication model is also much needed in the search for
soluble mediators released by loaded osteoblasts/osteo-
cytes to induce a procatabolic phenotype of articular
chondrocytes [44]. It was postulated that OA bone cells
when subjected to mechanical stimuli secrete novel soluble
mediators, which activate chondrocytes to produce degra-
dation enzymes. In order to decipher which soluble proteins
were involved in this crosstalk, a sophisticated technology,
Isobaric tags for relative and absolute quantitation (iTRAQ)
secretomic approach, was adopted to identify which pro-
teins were differentially present when a mechanical stress
was applied on bone cells. Although the preliminary results
were encouraging and a soluble protein (14-3-3ε) has been
identified, the role of this protein in the pathophysiology of
OA remains to be elucidated. Proteomic studies of key
mediators for the osteoblastechondrocyte communications
will provide a new insight into the pathogenesis of OA.
Limited to the slow growth rate of primarily cultured os-
teoblasts, pooling multiple samples for a single run may be
necessary to obtain sufficient proteins for a meaningful
proteomic analysis of osteoblasts or their secretory proteins
in a conditioned medium.
Concluding remarks and perspectives
Proteomics has been proven to be a powerful tool for OA
research, enabling researchers to identify the novel diag-
nostic biomarkers and therapeutic targets at an unprece-
dented pace. Yet the unsolved technical difficulties in
protein extraction and separation from OA tissues and cells
are the major issues that impede proteomic data from
being used clinically. The most common technical challenge
the researchers confront is the presence of abundantproteins that mask the signals of their minutely present
counterparts. Various techniques have been employed to
remove these massive signals of little interest, yet some
other proteins of interest might also be removed during the
process. For example, the interacting proteins were
depleted when prefractionation was done under non-
dissociating conditions. This phenomenon is particularly
pronounced when abundant proteins such as immunoglob-
ulins and albumin are removed from serum and synovial
fluid by extensive affinity chromatographic prefractiona-
tions, leading to poor data reproducibility which diminishes
the value of proteomic studies.
The protein profile of OA is far more complex than
previously thought. The posttranslational modifications of
proteins such as glycosylation should be worthy of further
investigation for OA. Some inflammation related proteins
were not differentially present and instead differentially
glycosylated in progressive or nonprogressive OA, which
were overlooked in conventional proteomic studies [28]. In
addition, glycoproteomics can identify a much higher
number of proteins [20]. It opens a door to hunt for more
biomarkers by using this technique, despite the fact that
glyco- or phosphoproteomic studies will cost more than
plain proteome studies. We do believe that the glyco- or
phosphoproteomic should be the next generation tools for
identifying differentially present proteins.
As there are difficulties in protein extraction and sep-
aration at tissue level, cellular proteomics may be an
alternative choice for studying OA. There is mounting ev-
idence showing the defects in OA osteoblast function by
producing proinflammatory cytokines and the collagen and
mineral with altered composition and ratio [39]. It may
account for the disturbances at OA subchondral bone.
Cellular and molecular proteomics into the respective
cellular pathways may give us hints to reveal the patho-
mechanism underlying defective osteoblasts in OA.
Secretory proteins mediating osteoblastechondrocyte
crosstalk could also be investigated by secretome analysis
of a conditioned medium. Pooling of samples can effec-
tively reduce the variations and improve the repeatability.
More accurate protein quantification approaches by means
of stable isotope labeling by/with amino acids in cell
culture (SILAC) and QconCAT for secretomics, or iTRAQ for
typical proteomics [12,45e47] may potentially yield more
meaningful and insightful data for biological pathway an-
alyses. The choice of the control is another important
issue in data interpretation of cellular proteomics. Oste-
oblasts derived from RA or osteoporotic bone may serve as
a disease positive control, and those from fractured and
biopsy from young adults should be regarded as a negative
control. Review articles regarding the proteomics in OA
mainly focused on the technical issues, in particular. Here,
we aim to interpret the existing proteomic data from OA
patients for identification of information gaps, in order to
shed light on the future direction of proteomics research
for OA.
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